Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

NCT04400331 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT04400331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04400331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Completed
Start date
September 18, 2020
Completion date
November 5, 2025
Enrollment
154 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chorea, huntington